Congratulations to Amber Therapeutics on the closing of their successful $100 million Series A financing. Lightstone is proud to be a fund partner and we look forward to updates as the company advances Amber-UI, their adaptive neuromodulation therapy for mixed urinary incontinence, towards US FDA approval. Full press release: https://bit.ly/3VzIHsD
Amber Tx successfully closes a $100 million Series A financing to advance breakthrough Amber-UI neuromodulation therapy for mixed urinary incontinence towards US FDA approval. US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI). Amber-UI has the unique potential to treat the millions of women who suffer from both urge and stress incontinence with a singular adaptive therapy. Read the full press release and learn more about our therapy approach on our website: https://lnkd.in/eZ7XthCy
congratulations Caroline G.